Oncology Institute Inc [TOI] stock is trading at $0.96, up 5.91%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TOI shares have gain 17.21% over the last week, with a monthly amount glided 140.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on September 14, 2022, and set its price target to $7. On August 15, 2022, Jefferies initiated with a Buy rating and assigned a price target of $10 on the stock.
Oncology Institute Inc [TOI] stock has fluctuated between $0.13 and $2.10 over the past year. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Oncology Institute Inc [NASDAQ: TOI] shares were valued at $0.96 at the most recent close of the market. An investor can expect a potential return of 733.33% based on the average TOI price forecast.
Analyzing the TOI fundamentals
Oncology Institute Inc [NASDAQ:TOI] reported sales of 378.93M for the trailing twelve months, which represents a growth of 21.78%. Gross Profit Margin for this corporation currently stands at 0.13% with Operating Profit Margin at -0.17%, Pretax Profit Margin comes in at -0.19%, and Net Profit Margin reading is -0.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -1.77 and Total Capital is -0.48. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 7.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9015 points at the first support level, and at 0.8418 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0144, and for the 2nd resistance point, it is at 1.0676.
Ratios To Look Out For
For context, Oncology Institute Inc’s Current Ratio is 2.49. As well, the Quick Ratio is 2.27, while the Cash Ratio is 1.01. Considering the valuation of this stock, the price to sales ratio is 0.19, the price to book ratio is 4.69.
Transactions by insiders
Recent insider trading involved Hively Brad, Director, that happened on Nov 26 ’24 when 0.25 million shares were purchased. Director, Hively Brad completed a deal on Dec 02 ’24 to buy 50000.0 shares.
